New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
Read More
Tag: Institute for Cancer Research London
Scientists identify link between genetic changes and rare childhood cancer rhabdomyosarcoma
Genetic changes could be used to guide treatment for the rare and aggressive cancer type
Read More
Early promise for new immunotherapy combo in brain cancer
Experimental drug plus immunotherapy demonstrated early potential in aggressive brain cancer
Read More
Cancer research in the UK faces ‘perfect storm’ of funding cuts
Experts have raised ‘serious concerns’ over government plans for UK science funding
Read More
ICR’s ‘resistance-busting’ drug advances into Phase I trial
EP0042 is a dual-inhibitor drug designed to block the activity of two cancer-driving proteins
Read More
Radiotherapy responses may be improved with targeted immunotherapy, study suggests
Researchers studied inflammation in bowel tumour samples taken before and after radiotherapy
Read More
ICR researchers identify potential new treatment for drug-resistant prostate cancer
CCS1477 has a novel mechanism of action compared to existing treatments
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
